User menu

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with relapsed AML following a short initial complete remission

Bibliographic reference Giles, FJ ; Ferrant, Augustin ; Karp, J ; Feldman, E ; Daenen, S ; et. al. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with relapsed AML following a short initial complete remission.46th Annual Scientific Meetign of the British-Society-for-Haematology (Edinburgh (England), Apr 03-05, 2006). In: British Journal of Haematology, Vol. 133, p. 64-64 (2006)
Permanent URL http://hdl.handle.net/2078.1/60063